|1.||Marks, Andrew R: 4 articles (09/2013 - 04/2002)|
|2.||Reiken, Steven: 3 articles (09/2013 - 03/2003)|
|3.||Long, Cheng: 2 articles (09/2014 - 07/2007)|
|4.||Kung, Fan-Lu: 2 articles (03/2014 - 11/2006)|
|5.||Liu, Fan-Lun: 2 articles (03/2014 - 11/2006)|
|6.||Andersson, Daniel C: 2 articles (09/2013 - 01/2012)|
|7.||Grip, Lars: 2 articles (06/2012 - 12/2009)|
|8.||Gerard, Melanie: 2 articles (08/2011 - 07/2011)|
|9.||Debyser, Zeger: 2 articles (08/2011 - 07/2011)|
|10.||Deleersnijder, Angélique: 2 articles (08/2011 - 07/2011)|
|1.||Nervous System Diseases (Neurological Disorders)
04/01/2005 - "Orally active non-FKBP-12 neuroimmunophilin ligands may be useful for the treatment of human neurological disorders without any potential side effects resulting from FKBP-12 binding."
11/01/2013 - "In addition, the neuroprotective mechanism of small-molecule FKBP12 ligands needs further study in order to develop them as novel drugs for treating neurological disorders."
05/01/2001 - "These results suggest that FKBP12 is not essential for the neurotrophic properties of immunophilin ligands, and immunophilin ligands are a new class of neuroprotective and neuroregenerative agents that may have therapeutic potential in a variety of neurological disorders."
12/08/2000 - "Following global ischemia, FKBP12 immunoreactivity in CA1 neurons decreased after 1 day, and then it was lost between 2 and 7 days, although many CA1 neurons showed a transient increase in FKBP12 at 2 days. "
12/25/2009 - "Myocardial release of FKBP12 and increased production of FKBP12.6 in ischemia and reperfusion experimental models."
01/01/2003 - "Following transient focal ischemia, we have analyzed the expression of FKBP12, 52 and 65 and the total FKBP enzyme activity. "
12/08/2000 - "Following focal ischemia, FKBP12 immunoreactivity decreased rapidly in the ischemic core by 4 h, but increased in surviving neurons in penumbra areas (4 h-7 days). "
12/25/2009 - "The primary aim of this study was to evaluate protein release into the myocardium in a porcine model during ischemia and reperfusion to search for clarifying models for reperfusion injury and secondarily to investigate release and production of the immunophilins FKBP12/12.6 in this model and in cell cultures. "
01/01/2011 - "All cases except one low grade tumor were strongly and diffusely stained with FKBP12. "
01/01/2011 - "Morphological and immunohistochemical features of malignant vascular tumors with special emphasis on GLUT1, and FKBP12 expressions."
04/01/2014 - "FKBP12 is an important target in the treatment of transplant rejection and is also a promising target for cancer and neurodegenerative diseases. "
07/15/2014 - "Unexpectedly Hsf1 activation was found to have a requirement for the rapamycin binding immunophilin FKBP12 even in the absence of rapamycin, while TORC1 "bypass" strains revealed that the rapamycin inhibition of yeast Hsf1 is not exerted through two of the major downstream targets of TORC1, the protein phosphatase regulator Tap42 and the protein kinase Sch9--the latter the ortholog of human S6 protein kinase 1. A problem with most of the Hsp90 inhibitor drugs now in cancer clinic trials is that they potently activate Hsf1. "
06/01/1997 - "Rapamycin did not promote IL-3 mRNA degradation in cells of a tumor variant lacking expression of FKBP12, the binding protein of rapamycin. "
|4.||Parkinson Disease (Parkinson's Disease)
10/01/2007 - "Thus, these studies clearly demonstrate that FKBP-12 is increased in the brain of a common animal model of Parkinson's disease (PD). "
08/01/2011 - "We focus on the role of FKBP12 in Parkinson's disease and propose it as a novel drug target for therapy of Parkinson's disease."
10/01/2007 - "In this report, we have utilized several analytical techniques, such as in situ hybridization, Western blotting, two-dimensional gel electrophoresis, and liquid chromatography electrospray tandem mass spectrometry to study the transcriptional expression as well as protein levels of FKBP-12 in the unilateral 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. "
07/29/2011 - "Both in vitro and cell culture data provide strong evidence that FKBP12 is the most important PPIase modulating α-SYN aggregation and validate the protein as an interesting drug target for Parkinson disease."
03/01/2001 - "These results suggest that inhibition of FKBP12 rotamase activity is not predictive for neurotrophic and neuroprotective properties of immunophilin ligands and question their therapeutic utility in neurodegenerative diseases like Parkinson's disease."
09/20/2002 - "Although the expressions of five FK506-binding protein (FKBP) mRNAs were detected in both SH-SY5Y (human neuroblastoma) and U251 (human glioma) cell lysates, the FKBP12 mRNA expression was detected in only the SH-SY5Y cells, and not the U251 cells. "
10/01/1997 - "In the present study, we show that the potent FKBP-12 inhibitor V-10,367, which lacks the structural components of FK506 required for calcineurin inhibition, increases neurite outgrowth in SH-SY5Y neuroblastoma cells and speeds nerve regeneration in the rat sciatic nerve crush model. "
|3.||tacrolimus binding protein 1B
|6.||Proteins (Proteins, Gene)
|9.||Oxidopamine (6 Hydroxydopamine)